Skip to main navigation Skip to search Skip to main content

Market Entry Agreements for Innovative Pharmaceuticals Subject to Indication Broadening: A Case Study for Pembrolizumab in The Netherlands

  • IQVIA Rotterdam

Research output: Contribution to journalArticleAcademicpeer-review

2 Citations (Scopus)
72 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Market Entry Agreements for Innovative Pharmaceuticals Subject to Indication Broadening: A Case Study for Pembrolizumab in The Netherlands'. Together they form a unique fingerprint.
Sort by

Pharmacology, Toxicology and Pharmaceutical Science